Preliminary results of an ongoing post-marketing study examining Janssen Pharmaceuticals' rivaroxaban (Xarelto) in patients with non-valvular atrial fibrillation (NVAF) indicate that the anti-clotting drug's safety in real-world settings is consistent with the findings of previous phase 3 clinical trials.
Mylan has announced the US launch of its lamivudine tablets, the generic version of GlaxoSmithKline's hepatitis B virus (HBV) treatment, Epivir-HBV.
Although the FDA previously warned health care professionals not to inject Wallcur's Practi-0.9% sodium chloride intravenous solution, given that the non-sterile product was for medical training purposes only, it was mistakenly administered to patients and is now being recalled.
AstraZeneca announced today that a study evaluating ticagrelor (Brilinta) for the secondary prevention of atherothrombotic events in patients with a history of heart attacks has met its primary efficacy endpoint.
Sanofi and Regeneron recently announced that their investigational hypercholesterolemia drug, alirocumab, met its primary efficacy endpoints in a pair of late-stage trials.
The FDA today approved AbbVie's Duopa (carbidopa and levodopa) enteral suspension for the treatment of motor fluctuations in patients with advanced Parkinson's disease.
Novartis announced that it has submitted New Drug Applications to the FDA for QVA149 and NVA237, investigational drugs for the long-term maintenance treatment of chronic obstructive pulmonary disease, following positive results from phase 3 trials of the drugs.
Results of a peer-reviewed clinical study support the use of pharmacy-based PharmaSmart kiosks in assessing hypertension, as the routine blood pressure testing on the kiosks was deemed comparable to daytime ambulatory blood pressure measurement.
The FDA has approved Daiichi Sankyo's anti-clotting drug, edoxaban (Savaysa), as a once-daily treatment to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
The FDA has acknowledged receipt of Actavis's resubmitted New Drug Application for its investigational atypical antipsychotic, cariprazine, which is indicated for the treatment of patients with schizophrenia and manic or mixed episodes associated with bipolar I disorder.
The FDA has approved Bayer HealthCare's gadobutrol injection for use with magnetic resonance imaging in pediatric patients aged
The FDA has approved Suneva Medical's dermal filler, Bellafill, for the treatment of moderate to severe, atrophic, distensible facial acne scars in patients aged >21 years.
Mylan and Teva have separately announced the US launches of their respective valsartan tablets, the generic version of Novartis' antihypertensive agent, Diovan.
Valeant Pharmaceuticals is voluntarily recalling a lot of its ribavirin powder for solution (Virazole) to the user level due to microbial contamination.
A supplemental new drug application for the use of Vertex Pharmaceuticals' ivacaftor in cystic fibrosis patients aged 6 years and older who have the R117H mutation in the cystic fibrosis transmembrane conductance regulator gene has been approved by the FDA.
The FDA has alerted health care professionals not to inject human or animal patients with Wallcur, LLC, IV products, which are for training purposes only.
No matter how well-intentioned they may seem, a loved one's critiques about weight often cause women to gain pounds instead of shedding them.
Treatment reduces duration of severe neutropenia in patients with nonmyeloid malignancies on anticancer drugs.
Treatment achieves 100% success rating during clinical trial.
Hospira is voluntarily recalling 10 lots of human and veterinary Mitoxantrone due to confirmed subpotency and elevated impurity levels.
Galderma Laboratories' Soolantra Cream, 1% has been approved by the FDA for the once-daily topical treatment of the inflammatory lesions, bumps, and pimples of rosacea.
Investigational drugs shut down critical genes and cancer cells responsible for tumor growth.
Teva's Granix Injection has been approved by the FDA for self-administration by patients and caregivers.
Experimental treatment effective in melanoma patients resistant to drugs that target BRAF.
Baxter International Inc has submitted a biologics license application to the FDA for the approval of BAX111, the first highly purified recombinant von Willebrand factor in clinical development as a treatment for von Willebrand disease.
Mylan Inc. has announced the US launch of its estradiol transdermal system, the generic version of Novartis' Vivelle-DOT.
Bethel Nutritional Consulting, Inc, is voluntarily recalling 1 lot of both SLIM-K Capsules and B-Lipo Capsules due to undeclared drug ingredients in each product.
The FDA today approved liraglutide (rDNA origin) injection (Saxenda) as a treatment option for chronic weight management alongside a reduced-calorie diet and physical activity.
Latanoprost eye drops may significantly reduce the risk of vision loss in patients with glaucoma.
A phase 3 study showed that Pfizer's pregabalin controlled-release formulation holds promise in adult patients with postherpetic neuralgia, the manufacturer announced in a press release.
